776 ITIL-306–201: A multicenter, first-in-human phase 1a/1b study of ITIL-306, an engineered autologous tumor-infiltrating lymphocyte (TIL) cell therapy product, in adults with advanced solid tumor

Abstract

Figure 2 ITIL-306-201 Phase 1a/1b Treatment Schema ITIL-306-201 is a phase 1a/1b dose escalation and expansion study evaluating the safety and feasibility of ITIL-306 in adult patients with advanced EOC, NSCLC, and RCC who relapsed from or are refractory to !1 prior line of systemic standard-of-care therapy. a Enrollment at the next dose level will be based on the incidence of dose-limiting toxicities observed within each dose level. Enrollment into Abstracts A806